Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention

Clinical Cancer Research

Volumn 18, Issue 13, 2012, Pages 3705-3713

  Hildebrandt, Michelle A T ^a   Lippman, Scott M ^a   Etzel, Carol J ^a   Kim, Edward ^a   Lee, J Jack ^a   Khuri, Fadlo R ^c   Spitz, Margaret R ^b   Lotan, Reuben ^a   Hong, Waun Ki ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RETINOID;

ARTICLE; CANCER PATIENT; CHEMOPROPHYLAXIS; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; ISOTRETINOIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RISK FACTORS; ROC CURVE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84863317475     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3271     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Khuri FR, Jain SR. Novel agents and incremental advances in the treatment of head and neck cancer. Semin Oncol 2004;31:3-10. (Pubitemid 38609786)
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
4. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
5. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:823-9. (Pubitemid 32738594)
6. Haughey BH, Gates GA, Arfken CL, Harvey J. Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann Otol Rhinol Laryngol 1992;101:105-12.
7. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801. (Pubitemid 20303877)
8. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994;86:140-1. (Pubitemid 24040154)
9. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98:441-50.
10. Lee J, Wu X, Hildebrandt MA, Yang H, Khuri FR, Kim E, et al. Global assessment of genetic variation influenceing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res 2011;4:185-93.
11. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 2002;99:13571-6. (Pubitemid 35215423)
12. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90. (Pubitemid 351758225)
13. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 2003; 112:1223-33. (Pubitemid 38056299)
14. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses Garcia A, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007;13: 4964-73. (Pubitemid 47502060)
15. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114:242-8. (Pubitemid 40194293)
16. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74. (Pubitemid 46962095)
17. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 1995;332:1405-10.
18. Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, et al. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J 2006;395:653-62.
19. Lefebvre B, Brand C, Flajollet S, Lefebvre P. Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway. Mol Endocrinol 2006;20:2109-21. (Pubitemid 44286708)
20. Chen L, Khillan JS. A novel signaling by vitamin A/retinol promotes self renewal of mouse embryonic stem cells by activating PI3K/Akt signaling pathway via insulin-like growth factor-1 receptor. Stem Cells 2010;28:57-63.
21. Ohashi E, Kogai T, Kagechika H, Brent GA. Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells. Cancer Res 2009;69:3443-50.
22. Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, et al. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res 2009;2:617-24.
23. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011;39:D945-50.
24. Yamauchi T, Kaburagi Y, Ueki K, Tsuji Y, Stark GR, Kerr IM, et al. Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase. J Biol Chem 1998;273: 15719-26. (Pubitemid 28298191)
25. Shepherd PR. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol Scand 2005;183: 3-12. (Pubitemid 40188032)
26. Gibson SL, Ma Z, Shaw LM. Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 2007;6:31-7.
27. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994;370:71-5.
28. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998;273: 14484-94. (Pubitemid 28319170)
29. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009;27:857-71.
30. Cleary JM, Shapiro GI. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep 2010;12: 87-94.